Supplementary Appendix

Size: px
Start display at page:

Download "Supplementary Appendix"

Transcription

1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life expectancy after myocardial infarction, according to hospital performance. N Engl J Med 2016;375: DOI: /NEJMoa

2 Life Expectancy after Myocardial Infarction by Hospital Performance SUPPLEMENTARY APPENDIX Emily M. Bucholz, M.D., Ph.D., M.P.H. Neel M. Butala, M.D., M.B.A. Sharon-Lise T. Normand, Ph.D. Shuangge Ma, Ph.D. Harlan M. Krumholz, M.D., S.M. 1

3 TABLE OF CONTENTS Supplementary Methods Pages Study Population 4 Outcome Variable 4 Calculation of Risk-Standardized Mortality Rates 4-5 Sample Stratification 5-6 Life Expectancy Calculations 6-7 Supplementary Tables Supplementary Appendix Table S Supplementary Appendix Table S Supplementary Appendix Table S Supplementary Appendix Table S4 15 Supplementary Figures Supplementary Appendix Figure S1 16 Supplementary Appendix Figure S2 17 Supplementary Appendix Figure S3 18 Supplementary Appendix Figure S4 19 Supplementary Appendix Figure S5 20 Supplementary Appendix Figure S6 21 Supplementary Appendix Figure S7 22 Supplementary Appendix Figure S Supplementary Appendix Figure S9 25 Supplementary Appendix Figure S10 26 Supplementary Appendix Figure S11 27 Supplementary Appendix Figure S12 28 Supplementary Appendix Figure S

4 Supplementary Appendix Figure S14 30 Supplementary Appendix Figure S

5 Supplementary Appendix Methods Study Population We analyzed data from the Cooperative Cardiovascular Project (CCP), a Health Care Financing Administration quality-improvement initiative for patients with acute myocardial infarction. The CCP included fee-for-service Medicare beneficiaries hospitalized with a principle discharge diagnosis of acute myocardial infarction (International Classification of Diseases, Ninth Revision, Clinical Modification, code 410), except acute myocardial infarction readmissions (code 410.x2). We did not have information on Medicare Advantage patients in CCP. The sample was identified from hospital bills in the Medicare National Claims History File (form UB-92). Each hospital was sampled for an 8-month period during the interval between February 1994 and July Trained personnel at centralized data abstraction centers abstracted patient records for information on patient demographics, medical history, presentation, laboratory and electrocardiographic data, in-hospital events, and treatment. In our analyses, we used similar inclusion criteria to those used in the established riskstandardized mortality rate measures to define our study cohort. Specifically, we limited our sample to patients 65 years of age or older with clinically confirmed acute myocardial infarction. Confirmed acute myocardial infarction was defined as an elevation of creatine kinase-mb (>5% of total creatine kinase), an elevation of lactate dehydrogenase level >1.5 times the upper limit of normal with isoenzyme reversal, or the present of 2 of the following: chest pain prior to admission, a 2-fold elevation in total creatine kinase, and electrocardiographic evidence of acute myocardial infarction (ST-segment elevation or new pathological Q-waves). When patients were hospitalized more than once during the study period, we used only the first admission. Consistent with current risk-standardized mortality rate models, we excluded patients admitted directly from ambulatory surgery or other acute hospital stays, patients transferred from other acute care hospitals, and patients who left the hospital against medical advice. Finally, we limited the analysis to only hospitals with at least 30 patients with a discharge diagnosis of acute myocardial infarction during the 8-month sample period in order to reliably estimate riskstandardized mortality rates. Outcome Variable We used data from the 1994 to 2012 Medicare Denominator files to ascertain survival over 17 years of follow-up. The Denominator files contain demographic and enrollment information on all Medicare fee-for-service beneficiaries in a given year, including dates of death. Time to death was defined as days from admission to the date of death and was censored at 17 years of follow-up. Calculation of Risk-Standardized Mortality Rates Calculations of risk-standardized mortality rates were performed using a medical record model described by Krumholz et al. 1 This model has been compared to the Medicare claims model now used for public reporting. Comparisons of hospital risk-standardized mortality rates from the Medicare claims model and the CCP medical record model showed strong agreement (correlation coefficient 0.90, SE 0.003) suggesting that they may be used as proxies for one another. Briefly, we used a hierarchical logistic model that linked the log-odds of mortality within 30 days of admission as a function of patient demographic and clinical variables, and a random hospital-specific effect. This approach accounts for the within-hospital correlation of observed outcomes and allows for the separation of within-hospital variation from between-hospital variation. We used the 31 variables previously identified in the medical record model to estimate hospital-specific mortality: 2 demographic, 7 medical history, and 22 presentation variables. Missing covariates were imputed using a single imputation approach, which allowed 4

6 incorporation of all patients into the model. A single imputation approach was preferred over a multiple imputation approach because we were unable to generate survival curves required for life expectancy calculations below with multiple imputations. Risk-standardized mortality rates are calculated as the ratio of predicted to expected mortality at a given hospital, multiplied by the national observed mortality rate. For each hospital, the denominator ( expected mortality) is the number of deaths expected within 30 days based on national mortality data for that hospital s case mix. It is calculated using a common intercept for all hospitals in the sample and thus, can be viewed as a measure of hospital case mix. The numerator ( predicted mortality) is the number of deaths predicted based on that specific hospital s performance. It is calculated using a hospital-specific intercept and is analogous to observed mortality. Conceptually, the ratio of predicted to expected mortality compares a particular hospital s performance to that of an average hospital with the same case mix. A lower rate reflects lower-than-expected mortality rates or better quality, whereas a higher rate reflects higher-than-expected mortality rates or worse quality. The c-statistic for the 30-day risk-standardized mortality rate model was (95% confidence interval ). To determine whether the 30-day risk-standardized mortality rate model had adequate model performance when predicting long-term outcomes, we repeated these calculations for 1-year, 5-year, and 10-year mortality in all patients and in 30-day survivors. As shown below, the 30-day risk-standardized mortality rate model provided good model discrimination (c-statistics ranging from ) over the long-term. C-statistics for risk-standard mortality rate models by duration of follow-up Duration of Follow-up All Patients 30-Day Survivors C-statistic (95% CI) C-statistic (95% CI) 30-day (0.768, 0.775) -- 1-year (0.779, 0.785) (0.769, 0.800) 5-year (0.802, 0.807) (0.793, 0.800) 10-year (0.816, 0.822) (0.810, 0.815) *Risk models were calculated using the methods described by Krumholz et al to calculate 30- day risk-standardized mortality rates. Specifically, hierarchical logistic regression was used to estimate the log-odds of mortality with a certain follow-up period. The models included the 31 variables previously identified in the medical record risk-standardized mortality rate model in addition to a random hospital-specific effect. The c-statistics provided represent the area under the survival curve and thus provide a measure of model discrimination. Sample Stratification To ensure that we were comparing life expectancy estimates between patients admitted to hospitals with similar case mix, we first stratified hospitals into quintiles based on their expected mortality (i.e. the denominator of the 30-day risk-standardized mortality rate model), which is a marker of case mix or patient risk (Figure 1). Life expectancy analyses were conducted separately for each case-mix stratum to permit comparisons of patients admitted to hospitals with similar case mix and to account for some of the heterogeneity in case mix across hospitals. Within each case-mix stratum, we ranked hospitals by risk-standardized mortality rate and grouped them into quintiles (Figure 1). These quintiles reflect hospital performance on 30- day mortality among hospitals with similar case mix and were the primary unit of analysis for all 5

7 life expectancy calculations. We used the terms high-performing and low-performing to refer to those hospitals with the lowest and highest 30-day mortality, respectively, within each casemix stratum. Baseline characteristics for patients admitted to hospitals in each case-mix stratum were calculated. Life Expectancy Calculations Life expectancy is defined as mean or expected survival and can be calculated as the area under the survival curve. We used a 3-step process to calculate life expectancy (Supplementary Appendix Figure S1). First, we fit a separate marginal Cox proportional hazards model within each case-mix stratum. The model included dummy variables for hospital performance quintile and patient age. Marginal models were applied to account for clustering of patients within hospitals. Proportional hazards assumptions were assessed using Schoenfeld residuals, examined graphically, and tested formally. Second, we plotted the expected survival curves separately for patients within each hospital performance quintile and extrapolated the curves to age 100 using exponential models. The constant hazard for the exponential model was specified as the average hazard over the last 2 years of follow-up, and the median age of each case-mix stratum was used to determine the number of years for extrapolation to age 100. For example, the mean age of the lowest case-mix stratum was 75 years, so for each riskstandardized mortality rate quintile in this case-mix stratum, we plotted the survival curve from the Cox model over 17 years of follow-up and then extrapolated the curve using an exponential model over an additional 8 years. We selected exponential models because we lacked information on the shape of the survival curves and thus chose a model with a constant hazard that does not make assumptions about changes to the hazard function over time. Similarly, we chose to extrapolate the curves to age 100 because the Centers for Disease Control and Prevention uses age 100 as the upper threshold for life expectancy estimates in the general population. Finally, mean life expectancy estimates were calculated by summing the areas under the individual Cox and exponential survival functions. Ninety-five percent confidence intervals were calculated using the same approach with the upper and lower confidence limits of the expected survival curves. We then calculated the years of life saved as the difference in life expectancy between patients treated at hospitals in the lowest and highest risk-standardized mortality rate quintiles within each case-mix stratum. To determine whether differences in life expectancy across risk-standardized mortality rate quintiles could be explained by differences in patient characteristics and treatment between hospitals, we repeated the life expectancy calculations above adjusting first for clinical characteristics and then for treatment characteristics. Two separate models were used for adjustment to determine whether differences in patient clinical characteristics or treatment across hospitals explained the differences in life expectancy between low and high performing hospitals. The clinical model included 35 sociodemographic, medical history, frailty, and clinical presentation characteristics, listed below. Sociodemographic Characteristics Medical History Variable Age Gender Race (white versus nonwhite) Income (defined using the 1990 Census median ZIP-code level household income) History of diabetes History of hypertension History of myocardial infarction History of coronary artery bypass grafting History of percutaneous coronary intervention 6

8 Frailty Measures Clinical Presentation History of cerebrovascular accident or transient ischemic attack History of chronic obstructive pulmonary disease History of congestive heart failure History of chronic kidney disease History of cancer Dementia or Alzheimer s disease Anemia (defined as hematocrit <30%) Current smoking Obesity (defined as body mass index on admission >30kg/m 2 ) Admission from a skilled nursing facility Immobility on admission (defined as requiring assistance with walking or immobile) Incontinent on admission (defined as occasionally incontinent, totally incontinent, or anuric) Heart rate on presentation Initial systolic blood pressure <100mmHg Shock within the first 48 hours of admission Heart failure within the first 48 hours of admission Duration of chest pain before presentation Blood urea nitrogen level Creatinine on admission White blood cell count on admission ST-elevation myocardial infarction Left bundle branch block on initial electrocardiogram Right bundle branch block on initial electrocardiogram Heart block on initial electrocardiogram Anterior or lateral myocardial infarction The treatment model adjusted for the same variables in the clinical model in addition to revascularization (percutaneous coronary intervention or coronary artery bypass grafting) within 30 days, fibrinolytic therapy during hospitalization, aspirin within 48 hours of admission, and beta-blockers within 48 hours of admission. To plot the expected survival curves from the Cox proportional hazards models, we needed to provide values for each of the covariates included in the model so we used covariate frequencies or mean values calculated among all patients in a given case-mix stratum. This approach estimates the effect of risk-standardized mortality rate quintile on life expectancy for an average patient in a given case-mix stratum. By using the same covariate values to plot the survival curves for each risk-standardized mortality rate quintile and thus forcing patients in all risk-standardized mortality rate quintiles to the have the same risk factor profile, we were able to compare life expectancy across quintiles for the average patient admitted to hospitals in a given case-mix stratum. Finally, to determine whether the survival benefit of being admitted to a higherperforming hospital occurred exclusively in the first 30 days or continued to increase after 30 days, we repeated unadjusted and adjusted life expectancy calculations among 30-day survivors only. The same methods and covariates were applied to calculate life expectancy and years of life saved in all patients and in 30-day survivors. Life expectancy was calculated from the time of admission for the overall cohort and from 30 days for 30-day survivors. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). 7

9 Supplementary Appendix Table S1. Patient clinical characteristics and treatment rates by hospital case mix (i.e. expected mortality) strata (n=119,735) Case-Mix Strata Clinical Presentation Overall N=119,735 Stratum 1 (i.e. hospitals that admitted the healthiest patients) N=21,054 Stratum 2 N=24,891 Stratum 3 N=26,228 Stratum 4 N=24,618 Stratum 5 (i.e. hospitals that admitted the sickest patients) N=22,944 p-value for trend* Initial SBP <0.001 <100mmHg 10,373 (8.7) 1318 (6.3) 1965 (7.9) 2148 (8.2) 2285 (9.3) 2657 (11.6) >100mmHg 108,778 (90.9) 19,686 (93.5) 22,834 (91.7) 23,949 (91.3) 22,196 (90.2) 20,113 (87.7) Missing 584 (0.5) 50 (0.2) 92 (0.4) 131 (0.5) 137 (0.6) 174 (0.8) Shock in first 48 hours 2934 (2.5) 258 (1.2) 468 (1.9) 627 (2.4) 684 (2.8) 897 (3.9) <0.001 Heart failure in first 48 hours 57,921 (48.4) 8922 (42.4) 11,498 (46.2) 12,643 (48.2) 12,546 (51.0) 12,312 (53.7) <0.001 Duration of chest pain before <0.001 presentation <6 hours 18,647 (15.6) 2386 (11.3) 3416 (13.7) 4042 (15.4) 4235 (17.2) 4568 (19.9) 6-12 hours 64,085 (53.5) 12,047 (57.2) 13,596 (54.6) 14,301 (54.5) 12,803 (52.0) 11,338 (49.4) >12 hours 10,682 (8.9) 2025 (9.6) 2273 (9.1) 2267 (8.6) 2207 (9.0) 1910 (8.3) No chest pain 16,047 (13.4) 2899 (13.8) 3406 (13.7) 3421 (13.0) 3285 (13.3) 3036 (13.2) Missing 10,274 (8.6) 1697 (8.1) 2200 (8.8) 2197 (8.4) 2088 (8.5) 2092 (9.1) 8

10 Blood urea nitrogen (mml), 7.81 (3.16) 7.34 (2.95) 7.59 (3.05) 7.78 (3.14) 7.99 (3.21) 8.33 (3.33) <0.001 mean (SD) 2322 (1.9) 535 (2.5) 513 (2.1) 463 (1.8) 424 (1.7) 387 (1.7) Missing Creatinine, mean (SD) 1.38 (0.97) 1.31 (0.85) 1.35 (0.88) 1.39 (1.04) 1.40 (0.95) 1.46 (1.10) <0.001 Missing 2651 (2.2) 509 (2.4) 514 (2.1) 588 (2.2) 581 (2.4) 459 (2.0) White blood cell count <0.001 < (6.5) 1589 (7.6) 1682 (6.8) 1711 (6.5) 1518 (6.2) 1290 (5.6) ,078 (61.9) 13,813 (65.6) 15,816 (63.5) 16,073 (61.3) 14,913 (60.6) 13,463 (58.7) >12 35,322 (29.5) 5169 (24.6) 6835 (27.5) 7832 (29.9) 7718 (31.4) 7768 (33.9) Missing 2545 (2.1) 483 (2.3) 558 (2.2) 612 (2.3) 469 (1.9) 423 (1.8) ST-elevation AMI 35,075 (29.3) 6058 (28.8) 7255 (29.2) 7662 (29.2) 7280 (29.6) 6820 (29.7) 0.19 Left bundle branch block <0.001 Yes 7894 (6.6) 1190 (5.7) 1617 (6.5) 1755 (6.7) 1707 (6.9) 1625 (7.1) No 105,521 (88.1) 18,704 (88.8) 21,946 (88.2) 23,096 (88.1) 21,656 (88.0) 20,119 (87.7) Missing 6320 (5.3) 1160 (5.5) 1328 (5.3) 1377 (5.3) 1255 (5.1) 1200 (5.2) Right bundle branch block <0.001 Yes 9273 (7.7) 1470 (7.0) 1876 (7.5) 1992 (7.6) 1984 (8.1) 1951 (8.5) No 104,142 (87.0) 18,424 (87.5) 21,687 (87.1) 22,859 (87.2) 21,379 (86.8) 19,793 (86.3) Missing 6320 (5.3) 1160 (5.5) 1328 (5.3) 1377 (5.3) 1255 (5.1) 1200 (5.2) 9

11 Heart Block 0.26 Yes 1688 (1.4) 269 (1.3) 359 (1.4) 352 (1.3) 373 (1.5) 335 (1.5) No 111,727 (93.3) 19,625 (93.2) 23,204 (93.2) 24,499 (93.4) 22,990 (93.4) 21,409 (93.3) Missing 6320 (5.3) 1160 (5.5) 1328 (5.3) 1377 (5.3) 1255 (5.1) 1200 (5.2) Anterior or lateral AMI 66,594 (55.6) (52.7) 13,651 (54.8) 14,509 (55.3) (57.1) 13,291 (57.9) <0.001 AMI location not noted 7638 (6.4) 1107 (5.3) 1431 (5.8) 1646 (6.3) 1724 (7.0) 1730 (7.5) <0.001 Killip Class > (37.8) 6680 (31.7) 8781 (35.3) 9805 (37.4) 10,000 (40.6) 9999 (43.6) <0.001 Pulse, mean (SD) 88.0 (24.9) 86.3 (23.9) 87.7 (25.0) 88.1 (24.9) 88.8 (25.2) 89.1 (25.4) <0.001 Treatment PCI/CABG within 30 days <0.001 Yes 35,958 (30.0) 7032 (33.4) 8137 (32.7) 7917 (30.2) 6881 (28.0) 5991 (26.1) No 81,878 (68.4) 13,704 (65.1) 16,634 (66.8) 17,677 (67.4) 17,382 (70.6) 16,481 (71.8) Missing 1899 (1.6) 318 (1.5) 120 (0.5) 634 (2.4) 355 (1.4) 472 (2.1) Fibrinolytic therapy in-hospital 21,510 (18.0) 4238 (20.1) 4764 (19.1) 4629 (17.7) 4171 (16.9) 3698 (16.1) <0.001 Aspirin on admission 68,924/91,297 12,843/ ,656/19,078 15,048/19,82 13,905/18,780 12,472/17,153 <0.001 (of eligible) (75.5) (78.0) (76.8) 7 (75.9) (74.0) (72.7) Beta-blockers on admission 34,075/55, /10, /12, /12, /10, / (of eligible) (61.4) (60.6) (60.8) (61.7) (62.4) (61.4) *P-values are for trend across all 5 case-mix strata. 10

12 Supplementary Appendix Table S2. Mean (95% confidence interval) unadjusted and adjusted life expectancy estimates (years) for all patients by case-mix strata and risk-standardized mortality rate quintile Case-Mix Strata Stratum 1 (i.e. hospitals that admitted Stratum 2 Stratum 3 Stratum 4 Stratum 5 (i.e. hospitals that admitted RSMR Quintile the healthiest patients) the sickest patients) Unadjusted Life Expectancy (years) 1(high-performing hospitals) 7.15 (6.95, 7.36) 6.56 (6.38, 6.74) 6.25 (6.09, 6.42) 5.90 (5.73, 6.07) 5.23 (5.06, 5.39) (6.72, 7.16) 6.18 (6.00, 6.37) 6.00 (5.82, 6.19) 5.61 (5.43, 5.79) 5.02 (4.85, 5.20) (6.72, 7.16) 5.97 (5.78, 6.17) 5.87 (5.68, 6.06) 5.32 (5.14, 5.51) 4.90 (4.73, 5.09) (6.32, 6.73) 5.95 (5.76, 6.15) 5.64 (5.46, 5.83) 5.12 (4.95, 5.30) 4.65 (4.49, 4.83) 5 (low-performing hospitals) 6.08 (5.88, 6.29) 5.62 (5.45, 5.79) 5.34 (5.18, 5.51) 4.95 (4.79, 5.12) 4.40 (4.24, 4.57) Clinically Adjusted Life Expectancy (years)* 1(high-performing hospitals) 7.40 ( ) 6.58 ( ) 6.13 ( ) 5.97 ( ) 5.45 ( ) ( ) 6.29 ( ) 5.87 ( ) 5.70 ( ) 5.13 ( ) ( ) 6.01 ( ) 5.82 ( ) 5.45 ( ) 5.07 ( ) ( ) 5.96 ( ) 5.47 ( ) 5.29 ( ) 4.78 ( ) 5 (low-performing hospitals) 6.20 ( ) 5.69 ( ) 5.18 ( ) 5.12 ( ) 4.52 ( ) Treatment Adjusted Life Expectancy (years) 1(high-performing hospitals) 7.22 ( ) 6.41 ( ) 5.92 ( ) 5.80 ( ) 5.27 ( ) 11

13 ( ) 6.21 ( ) 5.73 ( ) 5.55 ( ) 5.00 ( ) ( ) 5.96 ( ) 5.69 ( ) 5.33 ( ) 4.92 ( ) ( ) 5.89 ( ) 5.43 ( ) 5.23 ( ) 4.73 ( ) 5 (low-performing hospitals) 6.08 ( ) 5.66 ( ) 5.12 ( ) 5.03 ( ) 4.43 ( ) *Clinical model is adjusted for patient sociodemographic (age, gender, race, socioeconomic status), medical history (diabetes, hypertension, history of myocardial infarction, history of coronary artery bypass grafting, history of percutaneous coronary intervention, history of cerebrovascular accident or transient ischemic attack, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, cancer, dementia or Alzheimer s disease, anemia, current smoking, obesity), frailty (admission from a skilled nursing facility, immobility or incontinence on admission), and clinical presentation (heart rate on presentation, initial systolic blood pressure, shock within the first 48 hours of admission, duration of chest pain before presentation, blood urea nitrogen, creatinine, white blood cell count, ST-elevation myocardial infarction, left or right bundle branch block, heart block, anterior or lateral acute myocardial infarction). Treatment model is adjusted for those variables in the clinical model in addition to revascularization (percutaneous coronary intervention or coronary artery bypass grafting) within 30 days of admission, fibrinolytic therapy during hospitalization, aspirin, and beta-blockers on admission. 12

14 Supplementary Appendix Table S3. Mean (95% confidence interval) unadjusted and adjusted life expectancy estimates (years) for 30-day survivors by case-mix strata and risk-standardized mortality rate quintile (n=119,735) Case-Mix Strata Stratum 1 (i.e. hospitals that admitted Stratum 2 Stratum 3 Stratum 4 Stratum 5 (i.e. hospitals that admitted RSMR Quintile the healthiest patients) the sickest patients) Unadjusted Life Expectancy (years) 1(high-performing hospitals) 7.64 (7.43, 7.85) 7.52 (7.33, 7.72) 6.82 (6.65, 6.99) 6.87 (6.69, 7.06) 6.18 (6.00, 6.36) (7.41, 7.81) 7.32 (7.12, 7.53) 6.78 (6.59, 6.98) 6.84 (6.65, 7.04) 6.18 (5.99, 6.39) (7.57, 8.04) 7.24 (7.03, 7.46) 6.79 (6.59, 6.99) 6.66 (6.45, 6.88) 6.23 (6.03, 6.45) (7.31, 7.76) 7.43 (7.21, 7.66) 6.69 (6.49, 6.91) 6.59 (6.39, 6.81) 6.10 (5.90, 6.31) 5 (low-performing hospitals) 7.42 (7.19, 7.66) 7.37 (7.17, 7.59) 6.73 (6.54, 6.94) 6.55 (6.37, 6.73) 6.26 (6.05, 6.48) Clinically Adjusted Life Expectancy (years)* 1(high-performing hospitals) 7.78 ( ) 6.99 ( ) 6.63 ( ) 6.41 ( ) 6.06 ( ) ( ) 6.93 ( ) 6.53 ( ) 6.40 ( ) 5.90 ( ) ( ) 6.78 ( ) 6.67 ( ) 6.25 ( ) 6.01 ( ) ( ) 6.89 ( ) 6.40 ( ) 6.21 ( ) 5.86 ( ) 5 (low-performing hospitals) 7.37 ( ) 6.88 ( ) 6.39 ( ) 6.38 ( ) 5.98 ( ) Treatment Adjusted Life Expectancy (years) 1(high-performing hospitals) 7.62 ( ) 6.85 ( ) 6.46 ( ) 6.26 ( ) 5.90 ( ) 13

15 ( ) 6.84 ( ) 6.41 ( ) 6.25 ( ) 5.76 ( ) ( ) 6.71 ( ) 6.52 ( ) 6.13 ( ) 5.85 ( ) ( ) 6.79 ( ) 6.33 ( ) 6.12 ( ) 5.77 ( ) 5 (low-performing hospitals) 7.22 ( ) 6.79 ( ) 6.26 ( ) 6.25 ( ) 5.84 ( ) *Clinical model is adjusted for patient sociodemographic (age, gender, race, socioeconomic status), medical history (diabetes, hypertension, history of myocardial infarction, history of coronary artery bypass grafting, history of percutaneous coronary intervention, history of cerebrovascular accident or transient ischemic attack, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, cancer, dementia or Alzheimer s disease, anemia, current smoking, obesity), frailty (admission from a skilled nursing facility, immobility or incontinence on admission), and clinical presentation (heart rate on presentation, initial systolic blood pressure, shock within the first 48 hours of admission, duration of chest pain before presentation, blood urea nitrogen, creatinine, white blood cell count, ST-elevation myocardial infarction, left or right bundle branch block, heart block, anterior or lateral acute myocardial infarction). Treatment model is adjusted for those variables in the clinical model in addition to revascularization (percutaneous coronary intervention or coronary artery bypass grafting) within 30 days of admission, fibrinolytic therapy during hospitalization, aspirin, and beta-blockers on admission. 14

16 Supplementary Appendix Table S4. Distribution of acute myocardial infarction treatment rates across risk-standardized mortality rate quintiles within case-mix strata RSMR Quintile 1 RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 Chi-Square p-value for trend PCI/CABG within 30-days Case-Mix Stratum Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum Case-Mix Stratum Fibrinolytic therapy in-hospital Case-Mix Stratum Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Aspirin on admission (of ideal candidates) Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Beta-blockers on admission (of ideal candidates) Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <0.001 Case-Mix Stratum <

17 1. Fit a Cox proportional hazards model with age and risk-standardized mortality rate quintile 2. Plotted risk-standardized mortality rate quintile-specific expected survival curves 3A. Calculated average hazard (λ) over last 2 years of available follow-up 3B. Extrapolated the curve to age 100 using exponential model Supplementary Appendix Figure S1. A 3-step process was used to calculate life expectancy after acute myocardial infarction. Caption: Mean life expectancy was calculated as the area under the risk-standardized mortality rate quintile-specific survival curves. First, a Cox proportional hazards model was fit for each case-mix stratum modeling age and risk-standardized mortality rate quintile. risk-standardized mortality rate quintile-specific expected survival curves were plotted over the 17 years of available follow-up. An exponential model was used to extrapolate the survival curves beyond 17 years. The constant hazard for the exponential models was specified as the average hazard over the last two years of follow-up. The area under the survival curves were summed for mean life expectancy. 16

18 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S2. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for all patients admitted to hospitals in case-mix stratum 1 (i.e. hospitals that admitted the healthiest patients). 17

19 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S3. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for all patients admitted to hospitals in case-mix stratum 2. 18

20 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S4. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for all patients admitted to hospitals in case-mix stratum 3. 19

21 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S5. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for all patients admitted to hospitals in case-mix stratum 4. 20

22 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S6. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for all patients admitted to hospitals in case-mix stratum 5 (i.e. hospitals that admitted the sickest patients). 21

23 Life Expectancy after Acute Myocardial Infarction (years) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) 0 Case-Mix Stratum 1 (Hospitals that admitted the healthiest patients) Case-Mix Stratum 2 Case-Mix Stratum 3 Case-Mix Stratum 4 Case-Mix Stratum 5 (Hospitals that admitted the sickest patients) Supplementary Appendix Figure S7. Mean unadjusted life expectancy after acute myocardial infraction (years) by riskstandardized mortality rate (RSMR) quintile calculated from admission. Caption: Models for the calculation of life expectancy were run separately for each case-mix stratum. Higher case-mix stratum signifies hospitals that admitted sicker patients with higher expected mortality. Within each case-mix stratum, higher risk-standardized mortality rate quintile indicates lower-performing hospitals with a higher than expected mortality rate. 22

24 Life Expectancy after Acute Myocardial Infarction (years) Case-Mix Stratum 1 (Hospitals that admitted the healthiest patients) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Case-Mix Stratum 2 Case-Mix Stratum 3 Case-Mix Stratum 4 Case-Mix Stratum 5 (Hospitals that admitted the sickest patients) Supplementary Appendix Figure S8. Mean clinically adjusted life expectancy after acute myocardial infarction (years) by riskstandardized mortality rate (RSMR) quintile calculated from admission. Caption: Models for the calculation of life expectancy were run separately for each case-mix stratum. Higher case-mix stratum signifies hospitals that admitted sicker patients with higher expected mortality. Within each case-mix stratum, higher risk-standardized mortality rate quintile indicates lower-performing hospitals with a higher than expected mortality rate. The clinical is adjusted for patient sociodemographic (age, gender, race, socioeconomic 23

25 status), medical history (diabetes, hypertension, history of myocardial infarction, history of coronary artery bypass grafting, history of percutaneous coronary intervention, history of cerebrovascular accident or transient ischemic attack, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, cancer, dementia or Alzheimer s disease, anemia, current smoking, obesity), frailty (admission from a skilled nursing facility, immobility or incontinence on admission), and clinical presentation (heart rate on presentation, initial systolic blood pressure, shock within the first 48 hours of admission, duration of chest pain before presentation, blood urea nitrogen, creatinine, white blood cell count, ST-elevation myocardial infarction, left or right bundle branch block, heart block, anterior or lateral acute myocardial infarction). 24

26 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S9. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for 30-day survivors admitted to hospitals in case-mix stratum 1 (i.e. hospitals that admitted the healthiest patients). 25

27 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S10. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for 30-day survivors admitted to hospitals in case-mix stratum 2. 26

28 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S11. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for 30-day survivors admitted to hospitals in case-mix stratum 3. 27

29 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S12. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for 30-day survivors admitted to hospitals in case-mix stratum 4. 28

30 Survival (%) Time (days) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Supplementary Appendix Figure S13. Unadjusted expected survival curves by risk-standardized mortality rate (RSMR) quintile for 30-day survivors admitted to hospitals in case-mix stratum 4 (i.e. hospitals that admitted the sickest patients). 29

31 Life Expectancy after Acute Myocardial Infarction (years) Case-Mix Stratum 1 (Hospitals that admitted the healthiest patients) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Case-Mix Stratum 2 Case-Mix Stratum 3 Case-Mix Stratum 4 Case-Mix Stratum 5 (Hospitals that admitted the sickest patients) Supplementary Appendix Figure S14. Mean unadjusted life expectancy after acute myocardial infarction (years) by riskstandardized mortality rate (RSMR) quintile for 30-day survivors. Caption: Models for the calculation of life expectancy were run separately for each case-mix stratum. Higher case-mix stratum signifies hospitals that admitted sicker patients with higher expected mortality. Within each case-mix stratum, higher risk-standardized mortality rate quintile indicates lower-performing hospitals with a higher than expected mortality rate. 30

32 Life Expectancy after Acute Myocardial Infarction (years) Case-Mix Stratum 1 (Hospitals that admitted the healthiest patients) RSMR Quintile 1 (High-Performing) RSMR Quintile 2 RSMR Quintile 3 RSMR Quintile 4 RSMR Quintile 5 (Low-Performing) Case-Mix Stratum 2 Case-Mix Stratum 3 Case-Mix Stratum 4 Case-Mix Stratum 5 (Hospitals that admitted the sickest patients) Supplementary Appendix Figure S15. Mean clinically adjusted life expectancy after acute myocardial infarction (years) by riskstandardized mortality rate (RSMR) quintile for 30-day survivors. Caption: Models for the calculation of life expectancy were run separately for each case-mix stratum. Higher case-mix stratum signifies hospitals that admitted sicker patients with higher expected mortality. Within each case-mix stratum, higher risk-standardized mortality rate quintile indicates lower-performing hospitals with a higher than expected mortality rate. The clinical model is adjusted for patient sociodemographic (age, gender, race, socioeconomic 31

33 status), medical history (diabetes, hypertension, history of myocardial infarction, history of coronary artery bypass grafting, history of percutaneous coronary intervention, history of cerebrovascular accident or transient ischemic attack, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, cancer, dementia or Alzheimer s disease, anemia, current smoking, obesity), frailty (admission from a skilled nursing facility, immobility or incontinence on admission), and clinical presentation (heart rate on presentation, initial systolic blood pressure, shock within the first 48 hours of admission, duration of chest pain before presentation, blood urea nitrogen, creatinine, white blood cell count, ST-elevation myocardial infarction, left or right bundle branch block, heart block, anterior or lateral acute myocardial infarction). 32

Life Expectancy after Myocardial Infarction, According to Hospital Performance

Life Expectancy after Myocardial Infarction, According to Hospital Performance The new england journal of medicine Original Article Life Expectancy after Myocardial Infarction, According to Hospital Performance Emily M. Bucholz, M.D., Ph.D., M.P.H., Neel M. Butala, M.D., Shuangge

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Mortality Measures Set

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set

More information

Appendix Identification of Study Cohorts

Appendix Identification of Study Cohorts Appendix Identification of Study Cohorts Because the models were run with the 2010 SAS Packs from Centers for Medicare and Medicaid Services (CMS)/Yale, the eligibility criteria described in "2010 Measures

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable

More information

APPENDIX EXHIBITS. Appendix Exhibit A2: Patient Comorbidity Codes Used To Risk- Standardize Hospital Mortality and Readmission Rates page 10

APPENDIX EXHIBITS. Appendix Exhibit A2: Patient Comorbidity Codes Used To Risk- Standardize Hospital Mortality and Readmission Rates page 10 Ross JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand ST, et al. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. Health Aff (Millwood).

More information

In each hospital-year, we calculated a 30-day unplanned. readmission rate among patients who survived at least 30 days

In each hospital-year, we calculated a 30-day unplanned. readmission rate among patients who survived at least 30 days Romley JA, Goldman DP, Sood N. US hospitals experienced substantial productivity growth during 2002 11. Health Aff (Millwood). 2015;34(3). Published online February 11, 2015. Appendix Adjusting hospital

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Aspirin, Beta-Blocker, and Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With End-Stage Renal Disease and an Acute Myocardial Infarction

Aspirin, Beta-Blocker, and Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With End-Stage Renal Disease and an Acute Myocardial Infarction Journal of the American College of Cardiology Vol. 42, No. 2, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00572-2

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Trends in Clinical, Demographic, and Biochemical Characteristics of Patients with Acute Myocardial Infarction from 2003 to 2008: A Report from the American Heart Association Get with the Guidelines Coronary

More information

APPENDIX: Supplementary Materials for Advance Directives And Nursing. Home Stays Associated With Less Aggressive End-Of-Life Care For

APPENDIX: Supplementary Materials for Advance Directives And Nursing. Home Stays Associated With Less Aggressive End-Of-Life Care For Nicholas LH, Bynum JPW, Iwashnya TJ, Weir DR, Langa KM. Advance directives and nursing home stays associated with less aggressive end-of-life care for patients with severe dementia. Health Aff (MIllwood).

More information

Appendix 1: Supplementary tables [posted as supplied by author]

Appendix 1: Supplementary tables [posted as supplied by author] Appendix 1: Supplementary tables [posted as supplied by author] Table A. International Classification of Diseases, Ninth Revision, Clinical Modification Codes Used to Define Heart Failure, Acute Myocardial

More information

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group.

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR,

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: Version 4.3a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Mortality Measures Set

More information

Regional Density Of Cardiologists And Mortality For Acute Myocardial Infarction And Heart Failure

Regional Density Of Cardiologists And Mortality For Acute Myocardial Infarction And Heart Failure Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2014 Regional Density Of Cardiologists And Mortality For Acute

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Joshua A Salomon, Anushka Patel, Bruce Neal, Paul Glasziou, Diederick E. Grobbee,

More information

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018 Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report May 2018 Prepared by the Canadian Cardiovascular Society (CCS)/Canadian Society of Cardiac Surgeons (CSCS) Cardiac

More information

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group China PEACE risk estimation tool for inhospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic therapy Xi Li, Jing Li, Frederick A Masoudi, John

More information

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes. SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and

More information

Peter C. Austin Institute for Clinical Evaluative Sciences and University of Toronto

Peter C. Austin Institute for Clinical Evaluative Sciences and University of Toronto Multivariate Behavioral Research, 46:119 151, 2011 Copyright Taylor & Francis Group, LLC ISSN: 0027-3171 print/1532-7906 online DOI: 10.1080/00273171.2011.540480 A Tutorial and Case Study in Propensity

More information

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

NATIONAL QUALITY FORUM

NATIONAL QUALITY FORUM TO: NQF Members and Public FR: NQF Staff RE: Pre-comment review of an addendum to National Voluntary Consensus Standards: Cardiovascular Endorsement Maintenance 2010: A Consensus Report DA: October 6,

More information

PubH 7405: REGRESSION ANALYSIS. Propensity Score

PubH 7405: REGRESSION ANALYSIS. Propensity Score PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational

More information

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts

More information

Supplementary Table S1: Proportion of missing values presents in the original dataset

Supplementary Table S1: Proportion of missing values presents in the original dataset Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lee JS, Nsa W, Hausmann LRM, et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med. Published online September

More information

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early

More information

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX

More information

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant

More information

Supplementary Online Content

Supplementary Online Content 1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing

More information

A n aly tical m e t h o d s

A n aly tical m e t h o d s a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.

More information

TOTAL HIP AND KNEE REPLACEMENTS. FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES

TOTAL HIP AND KNEE REPLACEMENTS. FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES TOTAL HIP AND KNEE REPLACEMENTS FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES The Pennsylvania Health Care Cost Containment Council April 2005 Preface This document serves as

More information

Utilization of Cardiac Rehabilitation in Medicare

Utilization of Cardiac Rehabilitation in Medicare Chapter 7 Utilization of Cardiac Rehabilitation in Medicare Jose A. Suaya, MD, PhD, MBA, MPH Donald S. Shepard, PhD William B. Stason, MD, MSci This chapter describes a study that measures important predictors

More information

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice 10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170(21):1909-1917. eappendix.

More information

The New England Journal of Medicine. Special Articles OUTCOME OF ACUTE MYOCARDIAL INFARCTION ACCORDING TO THE SPECIALTY OF THE ADMITTING PHYSICIAN

The New England Journal of Medicine. Special Articles OUTCOME OF ACUTE MYOCARDIAL INFARCTION ACCORDING TO THE SPECIALTY OF THE ADMITTING PHYSICIAN Special Articles OUTCOME OF ACUTE MYOCARDIAL INFARCTION ACCORDING TO THE SPECIALTY OF THE ADMITTING PHYSICIAN JAMES G. JOLLIS, M.D., ELIZABETH R. DELONG, PH.D., ERIC D. PETERSON, M.D., M.P.H., LAWRENCE

More information

Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: New Measure Version 4.4a Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Episode-of-Care Payment Measures Set Measure ID #: PAYM-30-HF Performance

More information

Technical Notes for PHC4 s Report on CABG and Valve Surgery Calendar Year 2005

Technical Notes for PHC4 s Report on CABG and Valve Surgery Calendar Year 2005 Technical Notes for PHC4 s Report on CABG and Valve Surgery Calendar Year 2005 The Pennsylvania Health Care Cost Containment Council April 2007 Preface This document serves as a technical supplement to

More information

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927

More information

Improved control for confounding using propensity scores and instrumental variables?

Improved control for confounding using propensity scores and instrumental variables? Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Valley TS, Sjoding MW, Ryan AM, Iwashyna TJ, Cooke CR. Association of intensive care unit admission with mortality among older patients with pneumonia. JAMA. doi:10.1001/jama.2015.11068.

More information

Older individuals are at greatest risk for developing and

Older individuals are at greatest risk for developing and Decade Long Trends (2001 2011) in Duration of Pre-Hospital Delay Among Elderly Patients Hospitalized for an Acute Myocardial Infarction Raghavendra P. Makam, MD, MPH; Nathaniel Erskine, BS; Jorge Yarzebski,

More information

2013 Hypertension Measure Group Patient Visit Form

2013 Hypertension Measure Group Patient Visit Form Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part

More information

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart. Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

Rates and patterns of participation in cardiac rehabilitation in Victoria

Rates and patterns of participation in cardiac rehabilitation in Victoria Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human

More information

Patients with end-stage renal disease who require dialysis

Patients with end-stage renal disease who require dialysis Annals of Internal Medicine Article Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients Michael G. Shlipak, MD, MPH; Paul A. Heidenreich, MD,

More information

Writing Committee. ACP Performance Measurement Committee Members*

Writing Committee. ACP Performance Measurement Committee Members* Performance Measurement Coronary Artery Bypass Graft Surgery: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians Writing Committee Amir Qaseem,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Chan PS, Nallamothu BK, Krumholz HM, et al. Long-term outcomes

More information

THE NATIONAL QUALITY FORUM

THE NATIONAL QUALITY FORUM THE NATIONAL QUALITY FORUM National Voluntary Consensus Standards for Patient Outcomes Table of Measures Submitted-Phase 1 As of March 5, 2010 Note: This information is for personal and noncommercial use

More information

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0 Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately

More information

2011 Measures Maintenance Technical Report: Acute Myocardial Infarction, Heart Failure, and Pneumonia 30 Day Risk Standardized Readmission Measures

2011 Measures Maintenance Technical Report: Acute Myocardial Infarction, Heart Failure, and Pneumonia 30 Day Risk Standardized Readmission Measures 2011 Measures Maintenance Technical Report: Acute Myocardial Infarction, Heart Failure, and Pneumonia 30 Day Risk Standardized Readmission Measures Submitted By Yale New Haven Health Services Corporation

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,

More information

Mortality following acute myocardial infarction (AMI) in

Mortality following acute myocardial infarction (AMI) in In-Hospital Mortality Among Patients With Type 2 Diabetes Mellitus and Acute Myocardial Infarction: Results From the National Inpatient Sample, 2000 2010 Bina Ahmed, MD; Herbert T. Davis, PhD; Warren K.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Osler Journal Club Outcomes Research

Osler Journal Club Outcomes Research Osler Journal Club Outcomes Research Malenka DJ, et al. Outcomes Following Coronary Stenting in the Era of Bare-Metal vs. the Era of Drug- Eluting Stents. JAMA 2008; 299(24):2868-2876 Mentor: Dr. Boulware

More information

Consistent with the national priority of reducing racial disparities

Consistent with the national priority of reducing racial disparities Health Services and Outcomes Research Race, Socioeconomic Status, and Life Expectancy After Acute Myocardial Infarction Emily M. Bucholz, MD, PhD, MPH; Shuangge Ma, PhD; Sharon-Lise T. Normand, PhD; Harlan

More information

Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era

Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.

More information

Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction

Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction Renato D. Lopes, MD, PhD, MHS; Karen S. Pieper, MS; Susanna

More information

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,

More information

Epidemiology of Asthma. In Wayne County, Michigan

Epidemiology of Asthma. In Wayne County, Michigan Epidemiology of Asthma In Wayne County, Michigan Elizabeth Wasilevich, MPH Asthma Epidemiologist Bureau of Epidemiology Michigan Department of Community Health 517.335.8164 Publication Date: August 2005

More information

2016 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Readmission Measures

2016 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Readmission Measures 2016 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Readmission Measures Acute Myocardial Infarction Version 9.0 Chronic Obstructive Pulmonary Disease

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

patients actual drug exposure for every single-day of contribution to monthly cohorts, either before or

patients actual drug exposure for every single-day of contribution to monthly cohorts, either before or SUPPLEMENTAL MATERIAL Methods Monthly cohorts and exposure Exposure to generic or brand-name drugs were captured at an individual level, reflecting each patients actual drug exposure for every single-day

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate

PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate Measure Title Description Measure Type Data Source Level of Analysis Numerator HRS-3:

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic

More information

Technical Appendix for Outcome Measures

Technical Appendix for Outcome Measures Study Overview Technical Appendix for Outcome Measures This is a report on data used, and analyses done, by MPA Healthcare Solutions (MPA, formerly Michael Pine and Associates) for Consumers CHECKBOOK/Center

More information

Background- Methods-

Background- Methods- ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE- Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data Jing Li, Xi Li, Qing

More information

DOES PROCESS QUALITY OF INPATIENT CARE MATTER IN POTENTIALLY PREVENTABLE READMISSION RATES?

DOES PROCESS QUALITY OF INPATIENT CARE MATTER IN POTENTIALLY PREVENTABLE READMISSION RATES? DOES PROCESS QUALITY OF INPATIENT CARE MATTER IN POTENTIALLY PREVENTABLE READMISSION RATES? A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Jae Young Choi,

More information

ACUTE MYOCARDIAL INFARCtion

ACUTE MYOCARDIAL INFARCtion ORIGINAL CONTRIBUTION Primary Coronary Angioplasty vs for the Management of Acute Myocardial Infarction in Elderly Patients Alan K. Berger, MD Kevin A. Schulman, MD Bernard J. Gersh, MB, ChB, DPhil Sarmad

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD

More information

Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass

Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass http://www.kidney-international.org & 2008 International Society of Nephrology original article Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass Yijian

More information

Supplemental Material. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present

Supplemental Material. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present Supplemental Material Supplemental Appendix : Search Strategy Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 96 to Present. exp Contrast Media/ 907. exp Kidney Diseases/ 8.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

The Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction

The Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction PharmaSUG 2014 - Paper HA06 The Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction ABSTRACT Ashwini S Erande MPH University Of California

More information

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

DUKECATHR Dataset Dictionary

DUKECATHR Dataset Dictionary DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of

More information

Exercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE

Exercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE STUDY TITLE Exercise Behavior & Major Cardiac Events: CCSS 1 Association Between Exercise Behavior and Incidence of Major Cardiac Events in Adult Survivors of Childhood Cancer: A Report from the Childhood

More information

Ambarish Pandey, MD UT Southwestern Medical Center Dallas,

Ambarish Pandey, MD UT Southwestern Medical Center Dallas, Hospital Performance Based on 30-Day Risk Standardized Mortality and Long-Term Survival after Heart Failure Hospitalization An Analysis of the GWTG-HF Registry Ambarish Pandey, MD UT Southwestern Medical

More information

Statistical Analysis Plan

Statistical Analysis Plan The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

The table below includes the quality measures an ACO is required to submit to CMS as a participant in an MSSP Track 3 ACO

The table below includes the quality measures an ACO is required to submit to CMS as a participant in an MSSP Track 3 ACO The table below includes the quality measures an ACO is required to submit to CMS as a participant in an MSSP Track 3 ACO ACO-1 ACO-2 Getting Timely Care, Appointments, and Information How Well Your Providers

More information

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

Chapter 4: Cardiovascular Disease in Patients with CKD

Chapter 4: Cardiovascular Disease in Patients with CKD Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%

More information

Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years

Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years Introduction This document describes methods for calculating the quality performance benchmarks for Accountable

More information